Literature DB >> 23788443

Pulmonary hypertension in bronchopulmonary dysplasia: clinical findings, cardiovascular anomalies and outcomes.

Maria Jesús del Cerro1, Anna Sabaté Rotés, Antonio Cartón, Lucia Deiros, Montserrat Bret, Malaika Cordeiro, Cristina Verdú, Maria Isabel Barrios, Luis Albajara, Federico Gutierrez-Larraya.   

Abstract

OBJECTIVE: Pulmonary hypertension (PH) worsens the prognosis of bronchopulmonary dysplasia (BPD). The following items have not been fully established for PH in BPD: clinical characterization, incidence of cardiovascular anomalies (CVAs), response to PH treatment, and outcome. STUDY
DESIGN: A review of clinical records, computed tomography (CT) images and catheterization data of 36 patients with PH-BPD referred to our PH Unit (March 2006 to December 2011) was performed. Twenty-nine patients without major congenital heart defects and with complete follow-up data were included.
RESULTS: The diagnosis of PH was made at a median age of 4.5 months (IQR 2.4-7.8), with an echocardiography estimated median right ventricular pressure/systemic pressure ratio of 70% (IQR 60-80%). CT scanning was performed in 21 patients and catheterization in 14 patients. CVAs were found in 19 patients (65.5%): aortopulmonary collaterals (n = 9), pulmonary vein stenosis (n = 7), ASD (n = 4), and PDA (n = 9). Hemodynamic data: PVRI 4.3 UW m(2) (2.7-7); PVRI/SVRI 0.44 (0.32-0.8); and transpulmonary gradient 28 mmHg (19-40). At a median follow-up of 35 months (IQR 21-91), 6 patients had undergone shunts closure, 22 received specific PH drugs, 3 spontaneously improved of their PH, and 8 (26%) had died.
CONCLUSION: PH in BPD is not always a transient condition; it can be diagnosed at later stages and can have a protracted course. The incidence of associated CVAs is high. Prompt diagnosis, detection, and treatment of CVAs, and specific drug therapy can improve the outcome in these patients, although the mortality rate remains high.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  bronchopulmonary dysplasia; cardiovascular anomalies; echocardiography; premature infants; pulmonary hypertension

Mesh:

Year:  2013        PMID: 23788443     DOI: 10.1002/ppul.22797

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  54 in total

Review 1.  Primary pulmonary vein stenosis during infancy: state of the art review.

Authors:  David B Frank; Philip T Levy; Corey A Stiver; Brian A Boe; Christopher W Baird; Ryan M Callahan; Charles V Smith; Rachel D Vanderlaan; Carl H Backes
Journal:  J Perinatol       Date:  2021-03-05       Impact factor: 2.521

2.  Pulmonary endothelial cells exhibit sexual dimorphism in their response to hyperoxia.

Authors:  Yuhao Zhang; Xiaoyu Dong; Jasmine Shirazi; Jason P Gleghorn; Krithika Lingappan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-10       Impact factor: 4.733

Review 3.  Skeletal dysplasia: Respiratory management during infancy.

Authors:  Deepthi Alapati; Thomas H Shaffer
Journal:  Respir Med       Date:  2017-08-01       Impact factor: 3.415

4.  Pulmonary hypertension in the premature infant population: Analysis of echocardiographic findings and biomarkers.

Authors:  Michael G O'Connor; Divya Suthar; Kimberly Vera; James C Slaughter; Natalie L Maitre; Steven Steele; Amy Beller; Candice D Fike; Judy L Aschner; Paul E Moore; Eric D Austin
Journal:  Pediatr Pulmonol       Date:  2017-11-23

5.  Point Prevalence, Clinical Characteristics, and Treatment Variation for Infants with Severe Bronchopulmonary Dysplasia.

Authors:  Milenka Cuevas Guaman; Jason Gien; Christopher D Baker; Huayan Zhang; Eric D Austin; Joseph M Collaco
Journal:  Am J Perinatol       Date:  2015-03-04       Impact factor: 1.862

Review 6.  Pulmonary Hypertension in Children.

Authors:  Dunbar Ivy
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

7.  Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation.

Authors:  Gareth R Willis; Angeles Fernandez-Gonzalez; Jamie Anastas; Sally H Vitali; Xianlan Liu; Maria Ericsson; April Kwong; S Alex Mitsialis; Stella Kourembanas
Journal:  Am J Respir Crit Care Med       Date:  2018-01-01       Impact factor: 21.405

Review 8.  Pulmonary Hypertension and Vascular Abnormalities in Bronchopulmonary Dysplasia.

Authors:  Peter M Mourani; Steven H Abman
Journal:  Clin Perinatol       Date:  2015-09-26       Impact factor: 3.430

Review 9.  Stem cell-based therapies for the newborn lung and brain: Possibilities and challenges.

Authors:  S Alex Mitsialis; Stella Kourembanas
Journal:  Semin Perinatol       Date:  2016-01-15       Impact factor: 3.300

10.  Arginase and α-smooth muscle actin induction after hyperoxic exposure in a mouse model of bronchopulmonary dysplasia.

Authors:  Jennifer K Trittmann; Markus Velten; Kathryn M Heyob; Hanadi Almazroue; Yi Jin; Leif D Nelin; Lynette K Rogers
Journal:  Clin Exp Pharmacol Physiol       Date:  2018-02-06       Impact factor: 2.557

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.